🔴 Compass Pathways is trading 5% down today as investors reduce risk ahead of key data

Compass Pathways is trading 5% down at $11.73 amid pressure on high-beta biotech stocks and risk reduction ahead of key clinical milestones.

• No company-specific catalyst has been reported, with the move attributed to a broader cautious sentiment for speculative names.
• Investors are actively reducing risk exposure ahead of the upcoming COMP360 Phase 3 durability data release.